WallStreetZenWallStreetZen

NASDAQ: UBX
Unity Biotechnology Inc Stock

Overview
ForecastEarningsDividendOwnership
$1.50-0.01 (-0.66%)
Updated Apr 19, 2024
UBX Price
$1.50
Fair Value Price
-$0.49
Market Cap
$25.18M
52 Week Low
$1.50
52 Week High
$3.82
P/E
-0.56x
P/B
0.89x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$39.86M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.31
Operating Cash Flow
-$37M
Beta
1.13
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

UBX Overview

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Zen Score

–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how UBX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

UBX ($1.50) is overvalued by 408.34% relative to our estimate of its Fair Value price of -$0.49 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
UBX ($1.50) is not significantly undervalued (408.34%) relative to our estimate of its Fair Value price of -$0.49 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
UBX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more UBX due diligence checks available for Premium users.

Be the first to know about important UBX news, forecast changes, insider trades & much more!

UBX News

Valuation

UBX fair value

Fair Value of UBX stock based on Discounted Cash Flow (DCF)
Price
$1.50
Fair Value
-$0.49
Undervalued by
408.34%
UBX ($1.50) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
UBX ($1.50) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
UBX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

UBX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.56x
Industry
15.81x
Market
40.51x

UBX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.89x
Industry
5.74x
UBX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

UBX's financial health

Profit margin

Revenue
$0.0
Net Income
-$1.5M
Profit Margin
0%
UBX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$65.7M
Liabilities
$37.3M
Debt to equity
1.31
UBX's short-term assets ($46.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
UBX's short-term assets ($46.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
UBX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
UBX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$7.6M
Investing
$15.1M
Financing
$4.4M
UBX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

UBX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
UBX$25.18M-0.66%-0.56x0.89x
NKGN$25.22M+28.60%-0.21x-0.43x
ENLV$24.55M-5.71%-0.85x0.82x
SNSE$24.32M-1.32%-0.80x0.37x
SLGL$26.19M+4.44%-0.93x0.68x
View Top Biotech Stocks

Unity Biotechnology Stock FAQ

What is Unity Biotechnology's quote symbol?

(NASDAQ: UBX) Unity Biotechnology trades on the NASDAQ under the ticker symbol UBX. Unity Biotechnology stock quotes can also be displayed as NASDAQ: UBX.

If you're new to stock investing, here's how to buy Unity Biotechnology stock.

What is the 52 week high and low for Unity Biotechnology (NASDAQ: UBX)?

(NASDAQ: UBX) Unity Biotechnology's 52-week high was $3.82, and its 52-week low was $1.50. It is currently -60.73% from its 52-week high and at its 52-week low.

How much is Unity Biotechnology stock worth today?

(NASDAQ: UBX) Unity Biotechnology currently has 16,786,647 outstanding shares. With Unity Biotechnology stock trading at $1.50 per share, the total value of Unity Biotechnology stock (market capitalization) is $25.18M.

Unity Biotechnology stock was originally listed at a price of $166.50 in May 3, 2018. If you had invested in Unity Biotechnology stock at $166.50, your return over the last 5 years would have been -99.1%, for an annualized return of -61.01% (not including any dividends or dividend reinvestments).

How much is Unity Biotechnology's stock price per share?

(NASDAQ: UBX) Unity Biotechnology stock price per share is $1.50 today (as of Apr 19, 2024).

What is Unity Biotechnology's Market Cap?

(NASDAQ: UBX) Unity Biotechnology's market cap is $25.18M, as of Apr 20, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Unity Biotechnology's market cap is calculated by multiplying UBX's current stock price of $1.50 by UBX's total outstanding shares of 16,786,647.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.